ArticleBone marrow transplantation2023
On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone.
Anne Hubben, Danai Dima, Tahani Atieh, Chakra Chaulagain, Beth Faiman, Christina Ferraro, Sandra Mazzoni, Louis Williams, Christy Samaras, Jason Valent and 3 more
Open access · greenAbstract readLetter
In one paragraphArticle in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors at 3 institutions in 1 country.
Anne HubbenCleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH, USA. hubbena@ccf.org.ORCID 0000-0001-7382-2222 Tahani AtiehUniversity of Kansas, Department of Hematology and Medical Oncology, Kansas City, KS, USA.
Chakra ChaulagainCleveland Clinic Florida, Department of Hematology and Medical Oncology, Maroone Cancer Center, Weston, FL, USA.
Beth FaimanCleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH, USA.
Christina FerraroCleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH, USA.
Louis WilliamsCleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH, USA.
Christy SamarasCleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH, USA.
Jason ValentCleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH, USA.
Craig SauterCleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH, USA.
Jack KhouriCleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH, USA.
Cleveland Clinic · USCleveland Clinic Florida · USUniversity of Kansas · US
Funding
KUH-TN Training CoreTL1DK132770 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Evi X. Stavrou · 2021 to 2026
$2.5MNIDDK NIH HHS TL1 DK132770
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
AmyloidosisHematopoietic Stem Cell TransplantationHeterocyclic CompoundsMultiple MyelomaBenzylaminesGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem CellsHumansBenzylaminesGranulocyte Colony-Stimulating FactorHeterocyclic Compounds
Identifiers
PMID36828957
PMCPMC10164067
OpenAlexW4321790714
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390